Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Detecting and predicting neutralization of alemtuzumab responses in MS

Saxena, Gauri, Moore, James M., Jones, Meleri, Pryce, Gareth, Ali, Liaqat, Leisegang, Georgia R., Vijay, Vivek, Loveless, Samantha, Robertson, Neil P., Schmierer, Klaus, Giovannoni, Gavin, Gnananpavan, Sharmilee, Baker, David, Tallantyre, Emma C. and Kang, Angray S. 2020. Detecting and predicting neutralization of alemtuzumab responses in MS. Neurology, Neuroimmunology and Neuroinflammation 7 (4) , e767. 10.1212/NXI.0000000000000767

[img] PDF - Published Version
Download (800kB)

Abstract

Objective To test the hypothesis that antidrug antibodies (ADAs) against alemtuzumab could become relevant after repeated treatments for some individuals, possibly explaining occasional treatment resistance. Methods Recombinant alemtuzumab single-chain variable fragment antibody with a dual tandem nanoluciferase reporter linker was made and used to detect binding ADAs. Alemtuzumab immunoglobulin G Alexa Fluor 488 conjugate was used in a competitive binding cell-based assay to detect neutralizing ADAs. The assays were used to retrospectively screen, blinded, banked serum samples from people with MS (n = 32) who had received 3 or more cycles of alemtuzumab. Lymphocyte depletion was measured between baseline and about 1 month postinfusion. Results The number of individuals showing limited depletion of lymphocytes increased with the number of treatment cycles. Lack of depletion was also a poor prognostic feature for future disease activity. ADA responses were detected in 29/32 (90.6%) individuals. Neutralizing antibodies occurred before the development of limited depletion in 6/7 individuals (18.8% of the whole sample). Preinfusion, ADA levels predicted limited, postinfusion lymphocyte depletion. Conclusions Although ADAs to alemtuzumab have been portrayed as being of no clinical significance, alemtuzumab-specific antibodies appear to be clinically relevant for some individuals, although causation remains to be established. Monitoring of lymphocyte depletion and the antidrug response may be of practical value in patients requiring additional cycles of alemtuzumab. ADA detection may help to inform on retreatment or switching to another treatment.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Additional Information: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivatives License 4.0(CCBY-NC-ND)
Publisher: Lippincott, Williams & Wilkins: Creative Commons Attribution Non-Commercial No Derivatives License / Wolters Kluwer Health/LWW
ISSN: 2332-7812
Date of First Compliant Deposit: 15 January 2021
Date of Acceptance: 13 April 2020
Last Modified: 18 Jan 2021 14:45
URI: http://orca.cf.ac.uk/id/eprint/137711

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics